Amaryl®М SR: a New Release Form, New Possibilities for The Patients

Main Article Content

V.V. Роltorak
M.Yu. Gorshunska
N.S. Krasova


The review deals with a new form of oral antidiabetic drugs with a fixed dose — the combination of sustained-release metformin and glimepiride. Amaryl®M SR (2/500 mg) — a new dosage form, which provides a rapid release of glimepiride, and then the slow release of metformin from multipolymer hydrophilic matrix independently of pH. Based on the research of therapeutic efficacy and bioavailability, it is shown that this form is characterized by an optimal pharmacokinetics of metformin and glimepiride, does not increase the incidence of hypoglycemia, may be administered once a day, and is associated with less severe gastrointestinal side effects, as well as has more pronounced compliance. Application of Amaryl®M SR creates new possibilities for patients with type 2 diabetes mellitus in terms of optimizing glycemic control and quality of life.

Article Details

How to Cite
Роltorak V., M. Gorshunska, and N. Krasova. “Amaryl®М SR: A New Release Form, New Possibilities for The Patients”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 5.69, Nov. 2015, pp. 69-80, doi:10.22141/2224-0721.5.69.2015.75095.
To practicing Endocrinologists


Poltorak VV, Gorshunska MY. Sakharniy dyabet 2-ho typa: dva patohenetycheskykh defekta, dve mysheny dlya terapevtycheskoho vozdeystvyya. Liky Ukrayiny 2010;6(142):82-85.

Poltorak VV, Kravchun NS, Gorshunska MY, Krasova NS. Hlymepyryd (Amaryl) v terapyy bol'nykh sakharnym dyabetom 2 typa (patofyzyolohycheskoe obosnovanye y klynycheskaya realyzatsyya. Mizhnarodnyy endokrynolohichnyy zhurnal 2014;(1):77-89.

Poltorak VV, Krasova NS, Gorshunska MY. Hlykemycheskaya pamyat' kak patohenetycheskoe osnovanye dlya formyrovanyya alhorytma sovremennoy antydyabetycheskoy terapyy. Mizhnarodnyy endokrynolohichnyy zhurnal 2014;(3):15-21.

Poltorak VV, Krasova NS, Gorshunska MY. Kombynyrovannaya terapyya «metformyn+hlymepyryd» u bol'nykh sakharnym dyabetom 2-ho typa (molekulyarnye mekhanyzmy optymyzatsyy reabylytyruyushcheho deystvyya). Mizhnarodnyy endokrynolohichnyy zhurnal 2015;(1):87-97.

Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contribution of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired fasting glucose. Diabetes Care 2006; 29(5):1130-1139. doi:10.2337/dc05-2179.

Abrahamson MJ. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well! Diabetes Care 2015;38:160-169. doi: 10.2337/dc14-1945.

Ahmad NS, Ramli A, Islahudin F, Paraidathathu T. Medication adherence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia. Patient Preference and Adherence 2013;7:525-530. doi: 10.2147/PPA.S44698.

American Diabetes Association. Executive summary: Standards of medical care in diabetes-2014. Diabetes Care 2014;37(1):S5-S13. doi: 10.2337/dc14-S005.

Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-613. doi:10.7326/0003-4819-154-9-201105030-00336.

Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended release metformin tablets compared to immediate–release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004;20(4):565-572. doi: 10.1185/030079904125003278.

Caldwell LJ, Gardener CR, Cargll RC, inventors. Merck and Co, Inc, assignee. Drug delivery device which can be retained in the stomach for a controlled period of time. US patent 4, 767, 627. 30 Aug 1988.

Cefalu WT. Pharmacotherapy for the treatment of patients with type 2 diabetic mellitus: rationale and specific agents. Clin Pharmacol Ther 2007;81(5):636-649. doi:10.1038/sj.clpt.6100156.

Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetes patients. Diabet. Med. 2001;18(10):828-834. doi: 10.1046/j.1464-5491.2001.00582.x.

Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27(5):1218-1224. doi: 10.2337/diacare.27.5.1218.

Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81(11):4059-4067. doi: 10.1210/jcem.81.11.8923861.

Daily G, Kim MS, Lian JF. Patient compliance and persistence with anty-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res 2002;30(1): 71-79. doi: 10.1177/147323000203000111.

Daily GE. Glyburide/metformin tablets: A new therapeutic option for the management of type 2 diabetes. Expert Opin Pharmacoter 2003;4(8): 1417-1430. doi: 10.1517/14656566.4.8.1417.

Davis SN. The role of glimepiride in the effective management of type 2 diabetes. J Diabetes Complicat 2004;18(6): 367-376. doi: 10.1016/j.jdia-comp.2004.07.001.

Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B, Global Partnership for Effective Diabetes Management. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 2005;59(11):1345-1355. doi: 10.1111/j.1742-1241.2005.00674.x.

Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med 2002;19(4):279-284. doi: 10.1046/j.1464-5491.2002.00689.x.

Dunn CJ, Peters DH. Metformin. A review of its pharmalogical properties and therapeutic use in non-insulin – dependent diabetes mellitus. Drugs 1995;49(5):721-749. PMID: 7601013.

González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, Wacher-Rodarte N, Martínez-Abundis E, Aguilar-Salinas C, Islas-Andrade S, Arechavaleta-Granell R, González-Canudas J, Rodríguez-Morán M, Zavala-Suárez E, Ramos-Zavala MG, Metha R, Revilla-Monsalve C, Beltrán-Jaramillo TJ. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabet Complicat 2009;23(6):376-379. doi: 10.1016/j.jdiacomp.2008.09.002.

Gu N, Kim BH, Rhim H, Chung JY, Kim JR, Shin HS, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Comparison of the bioavailability and tolerability of fixed dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period, crossover study in healthy, Korean volunteers. Clin Ther 2010;32(7): 1408-1418. doi: 10.1016/j.clinthera.2010.07.012.

Gusler G, Gorsline J, Levy G, Zhang SZ, Weston IE, Naret D, Berner B. Pharmacokinetics of a metformin gastric-retentive tablets in healthy volunteers. J Clin Pharmacol. 2001;41(6):655-661. doi: 10.1177/00912700122010546.

Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double blind controlled study. Diabetes Care 1994;17(10):1100-1109. PMID: 7821128.

Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589. doi:10.1056/NEJMoa0806470.

Hwang YC, Kang M, Ahn CW, Park JS, Baik SH, Chung DJ, Jang HC, Kim KA, Lee IK, Min KW, Nam M, Park TS, Son SM, Sung YA, Woo JT, Park KS, Lee MK. Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimipiride/metformin twice daily in patients with type 2 diabetes. Int J Clin Pract 2013;67(3): 236-243. doi: 10.1111/ijcp.12071.

International Diabetes Federation. Diabetes Atlas. 6th edition Brussels Belgium: International Diabetes Federation; 2013.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149. doi: 10.2337/dc14-2441.

Javaz SAA, Soewondo P, Wang E, Admane K. PERSISTence on Glimepiride-Metformin (Amaryl M®) fixed combination in everyday practice in asian type 2 diabetes patients // 72nd Scientific sessions of American Diabetes Assoaciation, 8-12 June 2012, Philadelphia, USA. – Abstract 1124-P.

Johnson SB. Methodological issues in diabetes research. Measuring adherence. Diabetes Care 1992;15(11):1658-1667. PMID: 1468298.

Jojima T, Suzuki K, Hirama N, Uchida K, Hattori Y. Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-Akt-dependent pathway. Diabetes Obes Metab 2009; 11:143-149. doi:10.1111/j.1463-1326.2008.00923.x.

Kim BH, Shin KH, Kim J, Lim KS, Kim KP, Kim JR, Cho JY, Shin SG, Jang IJ, Yu KS. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way, crossover study in healthy, fasting Korean male volunteers. Clin Ther 2009;31(11): 2755-2764. doi: 10.1016/j.clinthera.2009.11.001.

Kim HS, Kim DM, Cha BS, Park TS, Kim KA, Kim DL, Chung CH, Park JH, Jang HC, Choi DS. Efficacy of glimepiride/metformin fixed dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low dose metformin monotherapy: A randomized open-label, parallel group, multicenter study in Korea. J Diabetes Invest 2014;5(6):701-708. doi: 10.1111/jdi.12201.

Kim KP, Lim KS, Kim BH, Shin HS, Cho JY, Shin SG, Jang IJ, Yu KS. Pharmacokinetics of a fixed-dose glimepiride/sustained-release metformin combination. Int J Clin Pharmacol Ther 2012;50(2):142-149. doi: 10.5414/CP201598.

Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, Jang WG, Cho WJ, Ha J, Lee IK, Lee CH, Choi HS. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008;57(2): 306-314. doi: 10.2337/db07-0381

Koshiba K, Nomura M, Nakaya Y, Ito S. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest 2006;53:87-94. doi:10.2152/jmi.53.87

Lee SH, Lee IK, Baik SH, Choi DS, Park KS, Song KH, Lee KW, Cha CW, Lee HW, Chung CH, Nam MS, Baek HS, Kim HY, Rhim HY, Son HY. Comparison of the efficacy and safety of glimepiride/metformin fixed combination versus free combination in patients with type 2 diabetes. multicenter, randomized, controlled trial. J Korean Diabetes Assoc 2006;30(6): 466-475. doi: 10.4093/jkda.2006.30.6.466.

Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003;88:531-537. doi: 10.1210/jc.2002-020904.

Lewin A, Lipetz R, Wu J, Schwartz S. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: multicenter, double-blind, randomized, controlled, phase III study. Clin Ther 2007;29(5): 844-855. doi: 10.1016/j.clinthera.2007.05.013.

Marathe PH, Arnold ME, Meeker J, Greene DS, Barbhaiya RH. Pharmacokinetics and bioavailability of a metformin/gliburide tablet administered alone and with food. J Clin Pharmacol 2000;40:1494-1502. doi: 10.1177/009127000004001222.

Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24(3):460-467. PMID: 11952029.

Nakamura I, Oyama J, Komoda H, Shiraki A, Sakamoto Y, Taguchi I, Hiwatashi A, Komatsu A, Takeuchi M, Yamagishi S, Inoue T, Node K. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report. Cardiovasc Diabetol 2014;13:2014. doi:10.1186/1475-2840-13-15

Noel DS. Kinetic study of normal and sustained release dosage forms of metformin in normal subjects. J Int Biomed Inform Data 1980;1:9-20.

Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patiens with type 2 diabetes. Metabolism 2011;60(1):1-23. doi: 10.1016/j.metabol.2010.09.010.

Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescipton medications. J Gen Intern Med. 2008;23(5): 611-614. doi: 10.1007/s11606-008-0544-x

Rendell M. The role of sulfonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64(12):1339-1358. PMID: 15200348.

Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008;14(2):71-75. PMID: 18269302.

Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 1995;35: 1094-1102. doi: 10.1002/j.1552-4604.1995.tb04033.x.

Schiekofer S, Rudofsky G Jr, Andrassy M, Schneider J, Chen J, Isermann B, Kanitz M, Elsenhans S, Heinle H, Balletshofer B, Häring HU, Schleicher E, Nawroth PP, Bierhaus A. Glimepiride reduces mononuclear activation of the redox-sensitive transcription factor nuclear factor-kappa B. Diabetes Obes Metab 2003;5(4):251-261. doi: 10.1046/j.1463-1326.2003.00270.x.

Shin KH, Kim SE, Yoon SH, Cho JY, Jang IJ, Shin SG, Yu KS. Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study. Clin Therap 2011;33:1809-1818. doi: 10.1016/j.clinthera.2011.10.003.

Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence 2013;7:419-434. doi: 10.2147/PPA.S44646.

Timmins P, Dennis AB, Vyas KA, inventors. Bristol-Myers Squibb Company, assignee. Biphasic controlled release delivery system for high solubility pharmaceuticals and method. US patent 6, 475, 521. 5 Nov 2002.

Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005;44(7):721-729. doi: 10.2165/2F00003088-200544070-00004.

Turner RC, Cull CA, Frighi V, Holman RR, UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281(21):2005-2012. doi: 10.1001/jama.281.21.2005.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-853. doi: 10.1016/S0140-6736(98)07019-6.

UK Prospective Diabetes Study (UKPDS) Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998;21(1):87-92. PMID: 9538975.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352(9131):854-865. doi: 10.1016/S0140-6736(98)07037-8.

Umpierrez G, Issa M, Vlajnic A. Glimepiride versus Pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: Results of a randomized clinical trial. Curr Med Res Opin 2006;22(4):751-759. doi: 10.1185/030079906X104786.

Weitgasser R, Lechleitner M, Luger A, Klingler A. Effects of glimepiride on HbA(1c) and body weight in type 2 diabetes: Results of a 1.5-year follow-up study. Diabetes Res Clin Pract 2003;61(1):13-19. doi: 10.1016/S0168-8227(02)00254-1.

Yu K-S, Handok Pharmaceuticals company Ltd. Seoul, Korea. - Bull Korean Chem Soc. 2011;(41):22-28.